BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis and biological evaluation of ezrin inhibitors targeting metastatic osteosarcoma. 2014

Mikell Paige, and George Kosturko, and Güllay Bulut, and Matthew Miessau, and Said Rahim, and Jeffrey A Toretsky, and Milton L Brown, and Aykut Üren
George Mason University, Department of Chemistry and Biochemistry, 10900 University Blvd, MS 1A9, Manassas, VA 20110, USA; Georgetown University Medical Center, Center for Drug Discovery, 3970 Reservoir Road, NW, The Research Building, Room EP07, Washington, DC 20057, USA. Electronic address: mpaige3@gmu.edu.

Respiratory failure due to pulmonary metastasis is the major cause of death for patients with osteosarcoma. However, the molecular basis for metastasis of osteosarcoma is poorly understood. Recently, ezrin, a member of the ERM family of proteins, has been associated with osteosarcoma metastasis to the lungs. The small molecule NSC 668394 was identified to bind to ezrin, inhibit in vitro and in vivo cell migration, invasion, and metastatic colony survival. Reported herein are the design and synthesis of analogues of NSC 668394, and subsequent functional ezrin inhibition studies. The binding affinity was characterized by surface plasmon resonance technique. Cell migration and invasion activity was determined by electrical cell impedance methodology. Optimization of a series of heterocyclic-dione analogues led to the discovery of compounds 21k and 21m as potential novel antimetastatic agents.

UI MeSH Term Description Entries
D001859 Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. Bone Cancer,Cancer of Bone,Cancer of the Bone,Neoplasms, Bone,Bone Neoplasm,Neoplasm, Bone
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D003598 Cytoskeletal Proteins Major constituent of the cytoskeleton found in the cytoplasm of eukaryotic cells. They form a flexible framework for the cell, provide attachment points for organelles and formed bodies, and make communication between parts of the cell possible. Proteins, Cytoskeletal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D012516 Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed) Sarcoma, Osteogenic,Osteogenic Sarcoma,Osteosarcoma Tumor,Osteogenic Sarcomas,Osteosarcoma Tumors,Osteosarcomas,Sarcomas, Osteogenic,Tumor, Osteosarcoma,Tumors, Osteosarcoma
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines

Related Publications

Mikell Paige, and George Kosturko, and Güllay Bulut, and Matthew Miessau, and Said Rahim, and Jeffrey A Toretsky, and Milton L Brown, and Aykut Üren
Identification of Novel Ezrin Inhibitors Targeting Metastatic Osteosarcoma by Screening Open Access Malaria Box.
November 2015, Molecular cancer therapeutics,
Mikell Paige, and George Kosturko, and Güllay Bulut, and Matthew Miessau, and Said Rahim, and Jeffrey A Toretsky, and Milton L Brown, and Aykut Üren
Design, Synthesis and Biological Evaluation of Novel MDH Inhibitors Targeting Tumor Microenvironment.
May 2023, Pharmaceuticals (Basel, Switzerland),
Mikell Paige, and George Kosturko, and Güllay Bulut, and Matthew Miessau, and Said Rahim, and Jeffrey A Toretsky, and Milton L Brown, and Aykut Üren
Design, synthesis and biological evaluation of novel tubulin inhibitors targeting colchicine sites.
March 2023, Bioorganic & medicinal chemistry letters,
Mikell Paige, and George Kosturko, and Güllay Bulut, and Matthew Miessau, and Said Rahim, and Jeffrey A Toretsky, and Milton L Brown, and Aykut Üren
Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR.
October 2013, ACS medicinal chemistry letters,
Mikell Paige, and George Kosturko, and Güllay Bulut, and Matthew Miessau, and Said Rahim, and Jeffrey A Toretsky, and Milton L Brown, and Aykut Üren
Design, Synthesis, and Biological Evaluation of Novel MAO-A Inhibitors Targeting Lung Cancer.
April 2022, Molecules (Basel, Switzerland),
Mikell Paige, and George Kosturko, and Güllay Bulut, and Matthew Miessau, and Said Rahim, and Jeffrey A Toretsky, and Milton L Brown, and Aykut Üren
Design, synthesis, and biological evaluation of novel covalent inhibitors targeting focal adhesion kinase.
December 2021, Bioorganic & medicinal chemistry letters,
Mikell Paige, and George Kosturko, and Güllay Bulut, and Matthew Miessau, and Said Rahim, and Jeffrey A Toretsky, and Milton L Brown, and Aykut Üren
Design, synthesis, and biological evaluation of multiple targeting antimalarials.
September 2021, Acta pharmaceutica Sinica. B,
Mikell Paige, and George Kosturko, and Güllay Bulut, and Matthew Miessau, and Said Rahim, and Jeffrey A Toretsky, and Milton L Brown, and Aykut Üren
Design, synthesis and biological evaluation of tyrosinase-targeting PROTACs.
December 2021, European journal of medicinal chemistry,
Mikell Paige, and George Kosturko, and Güllay Bulut, and Matthew Miessau, and Said Rahim, and Jeffrey A Toretsky, and Milton L Brown, and Aykut Üren
Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs.
January 2021, ACS medicinal chemistry letters,
Mikell Paige, and George Kosturko, and Güllay Bulut, and Matthew Miessau, and Said Rahim, and Jeffrey A Toretsky, and Milton L Brown, and Aykut Üren
Design, synthesis, and biological evaluation of HDAC6 inhibitors targeting L1 loop and serine 531 residue.
December 2023, European journal of medicinal chemistry,
Copied contents to your clipboard!